|
GB725228A
(en)
|
1952-06-19 |
1955-03-02 |
Roche Products Ltd |
Substituted carbamic acid esters and process for the manufacture thereof
|
|
BE640616A
(enExample)
|
1962-12-19 |
|
|
|
|
NL130759C
(enExample)
|
1965-10-07 |
|
|
|
|
US3492397A
(en)
|
1967-04-07 |
1970-01-27 |
Warner Lambert Pharmaceutical |
Sustained release dosage in the pellet form and process thereof
|
|
US4060598A
(en)
|
1967-06-28 |
1977-11-29 |
Boehringer Mannheim G.M.B.H. |
Tablets coated with aqueous resin dispersions
|
|
US3538214A
(en)
|
1969-04-22 |
1970-11-03 |
Merck & Co Inc |
Controlled release medicinal tablets
|
|
US4173626A
(en)
|
1978-12-11 |
1979-11-06 |
Merck & Co., Inc. |
Sustained release indomethacin
|
|
US4593034A
(en)
|
1984-04-06 |
1986-06-03 |
A. H. Robins Company, Inc. |
2-alkoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides
|
|
IE62231B1
(en)
|
1987-12-24 |
1995-01-11 |
Wyeth John & Brother Ltd |
Heterocyclic compounds
|
|
DE3878235T2
(de)
|
1988-08-04 |
1993-06-03 |
Synthelabo |
Antischizophren-wirksame s-n-(1-azabicyclo (2.2.2.)oct-3-yl)benzamide und thiobenzamide.
|
|
US5236838A
(en)
|
1988-12-23 |
1993-08-17 |
Genzyme Corporation |
Enzymatically active recombinant glucocerebrosidase
|
|
US5549892A
(en)
|
1988-12-23 |
1996-08-27 |
Genzyme Corporation |
Enhanced in vivo uptake of glucocerebrosidase
|
|
IT1228293B
(it)
|
1989-02-06 |
1991-06-07 |
Angeli Inst Spa |
Benzoderivati di composti eterociclici contenenti azoto.
|
|
DK443489D0
(da)
|
1989-09-08 |
1989-09-08 |
Ferrosan As |
Substituerede urinstofforbindelser, deres fremstilling og anvendelse
|
|
US5272071A
(en)
|
1989-12-22 |
1993-12-21 |
Applied Research Systems Ars Holding N.V. |
Method for the modification of the expression characteristics of an endogenous gene of a given cell line
|
|
GB9106571D0
(en)
|
1991-03-27 |
1991-05-15 |
Erba Carlo Spa |
Derivatives of substituted imidazol-2-one and process for their preparation
|
|
US5968502A
(en)
|
1991-11-05 |
1999-10-19 |
Transkaryotic Therapies, Inc. |
Protein production and protein delivery
|
|
WO1995021820A1
(en)
|
1994-02-10 |
1995-08-17 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel carbamate derivative and medicinal composition containing the same
|
|
JPH08198751A
(ja)
|
1995-01-19 |
1996-08-06 |
Yamanouchi Pharmaceut Co Ltd |
カルバメート誘導体
|
|
US5668144A
(en)
|
1995-11-08 |
1997-09-16 |
American Home Products Corporation |
1-azabicyclopheptane derivatives
|
|
SE9600683D0
(sv)
|
1996-02-23 |
1996-02-23 |
Astra Ab |
Azabicyclic esters of carbamic acids useful in therapy
|
|
TR199900185T2
(xx)
|
1996-07-29 |
1999-04-21 |
Pharmacia & Upjohn Ab |
Arisikloalkan karboksilik esterler, bunlar�n kullan�m�, farmakolojik bile�imler.
|
|
US6066626A
(en)
|
1997-10-29 |
2000-05-23 |
Genzyme Corporation |
Compositions and method for treating lysosomal storage disease
|
|
CN1332726A
(zh)
|
1998-11-02 |
2002-01-23 |
卫福有限公司 |
吡咯烷化合物及其药物用途
|
|
US6953855B2
(en)
|
1998-12-11 |
2005-10-11 |
Targacept, Inc. |
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
|
|
FR2791678B1
(fr)
|
1999-03-30 |
2001-05-04 |
Synthelabo |
Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
|
|
WO2001057008A1
(en)
|
2000-02-07 |
2001-08-09 |
Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft |
2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
|
|
GB0010955D0
(en)
|
2000-05-05 |
2000-06-28 |
Novartis Ag |
Organic compounds
|
|
AU6610001A
(en)
|
2000-06-27 |
2002-01-08 |
S A L V A T Lab Sa |
Carbamates derived from arylalkylamines
|
|
WO2002016356A2
(en)
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
|
AU2001284646A1
(en)
|
2000-08-21 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
HUP0303529A3
(en)
|
2000-12-22 |
2008-03-28 |
Almirall Ag |
New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
|
|
ES2275808T3
(es)
|
2001-02-06 |
2007-06-16 |
Pfizer Products Inc. |
Composiciones farmaceuticas para el tratamiento de trastornos del snc y otros trastornos.
|
|
JP2003267977A
(ja)
|
2002-03-14 |
2003-09-25 |
Yamanouchi Pharmaceut Co Ltd |
キヌクリジン誘導体
|
|
DE10211415A1
(de)
|
2002-03-15 |
2003-09-25 |
Bayer Ag |
Bicyclische N-Biarylamide
|
|
ES2203327B1
(es)
|
2002-06-21 |
2005-06-16 |
Almirall Prodesfarma, S.A. |
Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
US7985760B2
(en)
|
2002-07-17 |
2011-07-26 |
Actelion Pharmaceuticals Ltd. |
Piperidinetriol derivatives as inhibitors of glycosyceramid synthase
|
|
JPWO2004011430A1
(ja)
|
2002-07-25 |
2005-11-24 |
アステラス製薬株式会社 |
ナトリウムチャネル阻害剤
|
|
SE0202430D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
New Compounds
|
|
ES2462545T3
(es)
|
2002-12-06 |
2014-05-23 |
The Feinstein Institute For Medical Research |
Un procedimiento para la determinación de un agonista colinérgico selectivo para un receptor alfa7 nicotínico
|
|
WO2004056744A1
(en)
|
2002-12-23 |
2004-07-08 |
Janssen Pharmaceutica N.V. |
Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
|
|
US20050031683A1
(en)
*
|
2003-08-04 |
2005-02-10 |
Ashish Kapoor |
Solid pharmaceutical composition
|
|
TW200529860A
(en)
|
2003-12-22 |
2005-09-16 |
Astrazeneca Ab |
Nicotinic acetylcholine receptor ligands
|
|
GB0400812D0
(en)
|
2004-01-14 |
2004-02-18 |
Celltech R&D Ltd |
Novel compounds
|
|
JP2007186422A
(ja)
|
2004-01-28 |
2007-07-26 |
Astellas Pharma Inc |
アリールスルフィド誘導体
|
|
WO2006002375A2
(en)
|
2004-06-23 |
2006-01-05 |
The Feinstein Institute For Medical Research |
Method of treating ileus by pharmacological activation of cholinergic receptors
|
|
JP2008519840A
(ja)
|
2004-11-10 |
2008-06-12 |
ジェンザイム・コーポレイション |
糖尿病の処置方法
|
|
US20090131470A1
(en)
|
2005-06-11 |
2009-05-21 |
Vernalis R & D Limited |
Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
|
|
KR20080048550A
(ko)
|
2005-09-23 |
2008-06-02 |
메모리 파마슈티칼스 코포레이션 |
인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도
|
|
SG131819A1
(en)
|
2005-11-07 |
2007-05-28 |
Chikka Pte Ltd |
Buddy-based cross-carrier messaging system
|
|
US20090170847A1
(en)
|
2006-01-23 |
2009-07-02 |
Seung Chul Lee |
Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
|
|
WO2007100430A2
(en)
|
2006-01-27 |
2007-09-07 |
Yale University |
Cytisine and acetylcholine analogs and methods of treating mood disorders
|
|
US7840109B2
(en)
|
2006-08-14 |
2010-11-23 |
Adc Telecommunications, Inc. |
Factory spliced cable assembly
|
|
BRPI0806972A2
(pt)
|
2007-02-09 |
2014-04-08 |
Astellas Pharma Inc |
Composto cíclico contendo ponte azo
|
|
MX2009010557A
(es)
|
2007-03-30 |
2009-11-19 |
Amicus Therapeutics Inc |
Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
|
|
AU2008266960A1
(en)
|
2007-06-20 |
2008-12-24 |
Merck Sharp & Dohme Corp. |
Diphenyl substituted alkanes
|
|
EP2211856A4
(en)
|
2007-11-29 |
2011-02-09 |
Hospital For Sick Children |
COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER
|
|
JP2011529500A
(ja)
|
2008-07-28 |
2011-12-08 |
ジェンザイム コーポレーション |
虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害
|
|
EP2154136A1
(en)
|
2008-08-08 |
2010-02-17 |
CHIESI FARMACEUTICI S.p.A. |
Quinuclidine carbonate derivatives and medicinal compositions thereof
|
|
WO2010091104A1
(en)
|
2009-02-06 |
2010-08-12 |
Exelixis, Inc. |
Glucosylceramide synthase inhibitors
|
|
WO2010091164A1
(en)
|
2009-02-06 |
2010-08-12 |
Exelixis, Inc. |
Inhibitors of glucosylceramide synthase
|
|
WO2010121963A1
(en)
|
2009-04-21 |
2010-10-28 |
Nerviano Medical Sciences S.R.L. |
Resorcinol derivatives as hsp90 inhibitors
|
|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
JP2012533601A
(ja)
|
2009-07-23 |
2012-12-27 |
ノバルティス アーゲー |
運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
|
|
EP2470199B1
(en)
|
2009-08-28 |
2019-05-22 |
Icahn School of Medicine at Mount Sinai |
Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
|
|
US20110183938A1
(en)
|
2009-12-16 |
2011-07-28 |
Genentech, Inc. |
1,7-diazacarbazoles and methods of use
|
|
PT2568970T
(pt)
*
|
2010-05-10 |
2019-02-11 |
Lesvi Laboratorios Sl |
Formulações farmacêuticas estáveis contendo um anti-histamínico
|
|
RU2643807C1
(ru)
|
2010-11-12 |
2018-02-06 |
Сионоги Энд Ко., Лтд. |
Кристаллы производных 6,7-ненасыщенного-7-карбамоилморфинана и способ их получения
|
|
CN103917094B
(zh)
|
2011-03-18 |
2016-11-09 |
建新公司 |
葡萄糖基神经酰胺合酶抑制剂
|
|
US9845327B2
(en)
|
2011-06-22 |
2017-12-19 |
The General Hospital Corporation |
Treatment of proteinopathies
|
|
JP2014520126A
(ja)
|
2011-06-22 |
2014-08-21 |
イソケム |
ソリフェナシンおよびその塩の製造方法
|
|
EP2895187A4
(en)
|
2012-09-11 |
2015-12-02 |
Hospira Australia Pty Ltd |
DAPTOMYCIN FORMULATIONS AND USES THEREOF
|
|
MA37975B2
(fr)
|
2012-09-11 |
2021-03-31 |
Genzyme Corp |
Inhibiteurs de synthase de glucosylcéramide
|
|
JO3713B1
(ar)
*
|
2013-03-15 |
2021-01-31 |
Genzyme Corp |
أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
|
|
TW201900625A
(zh)
|
2013-03-15 |
2019-01-01 |
美商健臻公司 |
製備葡糖基神經醯胺合成酶抑制劑之方法
|
|
ES2871416T3
(es)
*
|
2013-12-11 |
2021-10-28 |
Genzyme Corp |
Inhibidores de glucosilceramida sintasa
|
|
TW201642855A
(zh)
|
2015-03-10 |
2016-12-16 |
健臻公司 |
用於治療蛋白質病變之方法
|
|
US12472144B2
(en)
*
|
2017-08-08 |
2025-11-18 |
Amneal Pharmaceuticals Llc |
Pharmaceutical composition comprising eliglustat
|
|
US12527776B2
(en)
|
2019-02-04 |
2026-01-20 |
Genzyme Corporation |
Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS)
|
|
WO2020163244A1
(en)
|
2019-02-04 |
2020-08-13 |
Genzyme Corporation |
Methods for treating symptoms and disorders associated with lysosomal storage diseases
|
|
WO2021061701A1
(en)
*
|
2019-09-25 |
2021-04-01 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of lucerastat salts and process for preparation thereof
|
|
EP4100009A1
(en)
|
2020-02-03 |
2022-12-14 |
Genzyme Corporation |
Methods for treating neurological symptoms associated with lysosomal storage diseases
|